Pricing Log in Create free account
Monday 9 November 2026 Export YARW’s income statement to Excel — free account

Yarrow Bioscience, Inc

YARW

Healthcare Biotechnology

Yarrow Bioscience, Inc’s revenue for fiscal 2025 (year ended December 2025) was $570,000.00, up 13.8% from fiscal 2024.

Revenue
+40.6%
EPS
+46.0%
Free cash flow
+81.6%

Quarter to June 2026, against a year earlier

15.60 2.00 +14.71%
Market cap
$147.2M
P/E
n/m
Fwd P/E
n/m
Dividend yield
0.10%
F-score
3/9
ROIC
0.00%
Net debt / EBITDA
1.0×
Dividend safety
20/100
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Net bought
—
Trades
0 sells · 0 buys
Ownership
0.00%

Capital & Financial Ratios $m

Size
Market Cap 147
Revenue ttm 0
Net income ttm (19)
Free cash flow ttm (17)
Net debt Q (23)
Valuation
P/E n/m
Forward P/E n/m
Price / sales 27.8 (above 10: high)
Forward P/S Powerpack
Price / FCF n/m
Price / book 0.6
Financial health
Current ratio Q 15.3 (at or above 1.5: strong)
Debt / equity Q n/m
Interest coverage Q (3.1)
Growth
Revenue growth Q +40.6% (above 0%: growing)
Operating income growth Q +58.9% (above 0%: growing)
EPS, this year +7.9%
EPS, next year A +5.8%
Revenue, next year A +1,093.0% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +49.8% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates; n/m is not meaningful, as a P/E on a loss. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 118×, against a ten-year median of 65.3×; over the ten years it ranged from −12.3× in 2020 to 295× in 2024.
P/S against its own 10 years 36.72%
10-year low 10-year high
P/B against its own 10 years 18.53%
10-year low 10-year high
EV/Sales against its own 10 years 68.95%
10-year low 10-year high

Dividends

Yield
0.10%
Annual rate
0.02
Payout ratio
—
  1. 0.02 ’26
paid change on the year, %

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 93 62 29 23
Receivables — — — —
Inventory — — — —
Other — — — —
96 64 30 24
2023 2024 2025 Q'26
Payables 2 3 1 1
ST’ Debt — — — —
Other 2 3 0 0
8 15 2 2

Compound Annual Growth %

10y 5y 3y
Sales 2.55% (51.39%) 6.12%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (0.63%) (5.83%) (3.82%)

EPS $

Mar Jun Sep Dec Year
’26 (4.00) (3.51) — — —
’25 (10.00) (6.50) (8.50) (5.64) (31.50)
’24 (7.50) (11.00) (14.50) (14.00) (46.50)
’23 (87.00) (154.50) (100.50) (9.89) (139.00)
’22 71.94 (134.89) (143.88) (166.50) (364.00)
’21 (377.70) (350.72) (368.70) (197.84) (1.28k)
’20 (3.42k) (4.35k) (539.57) (494.60) (7.09k)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 0 0 — — —
’25 0 0 0 0 1
’24 0 0 0 0 1
’23 0 0 0 0 0
’22 0 0 0 0 0
’21 0 0 0 0 1
’20 2 12 3 4 21
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (4) (2) — — —
’25 (11) (11) (7) (4) (33)
’24 (8) (8) (9) (9) (34)
’23 (5) (10) (5) (5) (25)
’22 (9) (8) (7) (5) (29)
’21 (13) (16) (18) (10) (56)
’20 (52) (36) (24) (25) (137)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (4) (2) — — —
’25 (11) (11) (7) (4) (33)
’24 (8) (8) (9) (9) (34)
’23 (5) (10) (5) (5) (25)
’22 (9) (8) (7) (5) (29)
’22 — — — — (29)
’21 (13) (16) (18) (10) (56)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 1 5 4 0 21 1 0 0 1 1 0 (1.8%) — — — —
Gross margin, % 100.00 100.00 100.00 100.00 93.37 100.00 100.00 100.00 100.00 100.00 100.00 0.0 pt
EBT (14) (29) (74) (95) (256) (45) (34) (28) (40) (27) (19) +7.4%
EBT margin, % (2,087.24) (634.57) (2,057.05) (21,524.60) (1,218.63) (4,796.56) (7,113.63) (6,573.58) (7,944.71) (4,689.82) (3,914.11) (2,602.6) pt
Net income (14) (29) (74) (95) (256) (73) (23) (28) (40) (26) (19) +7.3%
Per share, $
Per share, $ Revenue 481.43 3,272.86 500.39 47.13 583.14 16.28 7.49 2.06 0.59 0.67 0.56 (51.9%)
Earnings (10,147.25) (20,467.63) (10,322.72) (11,115.11) (7,086.33) (1,276.98) (364.00) (139.00) (46.50) (31.50) (21.65) (47.4%)
Cash flow (1,617.86) (20,158.57) (9,557.32) (7,807.87) (3,807.83) (985.44) (458.40) (123.31) (39.88) (38.72) (19.74) (33.9%)
Capex (22.14) (19.29) (77.53) (108.30) (3.14) 0.00 0.00 0.00 (0.14) 0.00 0.00 n/m
Free cash flow (1,640.00) (20,177.86) (9,634.85) (7,916.17) (3,810.97) (985.44) (458.40) (123.31) (40.02) (38.72) (19.74) (34.0%)
Book value 21,115.71 37,352.14 18,147.13 1,869.68 1,041.47 850.28 489.83 431.80 61.15 32.46 25.71 (51.3%)
Shares, m 0 0 0 0 0 0 0 0 1 1 1 +104.0%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S 31.58 31.58 16.76 36.12 9.75 56.40 16.52 168.21 284.78 43.54 27.77 69.5
P/B 0.00 0.00 0.82 6.37 5.46 1.08 0.25 0.80 2.74 0.89 0.61 1.8
EV/Sales 18.59 18.59 (4.63) 23.23 8.54 81.95 91.31 105.34 295.03 109.57 118.48 74.8
EV/FCF (3.01) (3.01) 0.43 (0.97) (1.31) (1.35) (1.49) (1.75) (4.33) (1.87) (3.34) (1.9)
Cash, $m
Cash, $m Operating cash flow (2) (28) (69) (73) (137) (56) (29) (25) (34) (33) (17) +34.7%
Capex 0 0 (1) (1) 0 — — — 0 — 0 +18.1%
Free cash flow (2) (28) (69) (74) (137) (56) (29) (25) (34) (33) (17) +34.5%
Balance, $m
Balance, $m Working capital 28 56 130 47 65 45 29 88 50 28 22 0.0%
Net debt (31) (60) (136) (41) (26) (43) (31) (93) (62) (29) (23) (0.7%)
Shareholders’ equity 30 52 130 18 37 49 31 89 52 28 22 (0.7%)
Returns, %
Returns, % ROA (33.45) (53.39) (71.73) (86.10) (292.24) (91.21) (43.06) (41.10) (48.40) (54.57) (54.77) (21.1) pt
ROIC 0.00 0.00 0.00 0.00 (1,406.53) (420.68) (9,442.46) 0.00 0.00 0.00 0.00 0.0 pt
ROE 47.78 67.25 (202.24) (128.66) (928.19) (170.28) (58.14) (47.44) (56.57) (66.33) (61.40) (114.1) pt
People
People Employees 32 32 43 40 106 28 12 10 13 10 — (12.1%)
Revenue/emp, $m 0.02 0.14 0.08 0.01 0.20 0.03 0.04 0.04 0.04 0.06 — +11.7%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

Yarrow Bioscience, Inc vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
MSLE Satellos Bioscience Inc. $152.6M — (loss-making) — — n/m −65.66% (below 0%: shrinking) 99.26% 0.00% Compare
YARW Yarrow Bioscience, Inc $147.2M — (loss-making) — (loss-making) +40.58% (above 0%: growing) n/m +81.56% (above 0%: growing) 100.00% (3,197.94%)
CMPX Compass Therapeutics, Inc. $136.7M — (loss-making) — (loss-making) — n/m −26.05% (below 0%: shrinking) 100.00% 0.00% Compare
CUE Cue Biopharma, Inc. $136.1M — (loss-making) — (loss-making) +166.66% (above 0%: growing) n/m −742.65% (below 0%: shrinking) 100.00% (1,113.30%) Compare
TARA Protara Therapeutics, Inc. $135.9M — (loss-making) — — n/m −28.10% (below 0%: shrinking) 0.00% 0.00% Compare
SPRB Spruce Biosciences, Inc. $133.8M — (loss-making) — (loss-making) −75.86% (below 0%: shrinking) n/m −152.10% (below 0%: shrinking) 100.00% 0.00% Compare
MENS Jyong Biotech Ltd. $133.6M — — — — — — — Compare
PDSB PDS Biotechnology Corporation $129.2M — (loss-making) — — n/m +69.32% (above 0%: growing) 0.00% 0.00% Compare
MOLN Molecular Partners AG Sponsored ADR $119.2M — (loss-making) — (loss-making) −98.86% (below 0%: shrinking) n/m +11.07% (above 0%: growing) 0.00% 0.00% Compare
Median of peers $134.9M — — −75.86% — −28.10% 99.26% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 12 November 2025

Ownership

Directors and executive officers, together 3.03%
AI Biotechnology LLC 9.99%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Yarrow Bioscience, Inc (YARW) Latest News

6 Nov

Impact 3 · · Investing.com
Impact 3 · · Zacks
Impact 3 · · GlobeNewswire

14 Sep

Impact 4 ·

10 Sep

Impact 4 ·
Impact 3 ·

13 Aug

Impact 3 ·

27 Jul

Impact 4 ·
Impact 4 ·

23 Jul

Impact 4 ·

21 Jul

Impact 4 ·

10 Jul

Impact 4 ·

17 Dec

Impact 4 · · GlobeNewswireSouth China Morning PostMotley FoolSimply Wall St.
Impact 3 · · Associated Press Finance

18 Aug

Impact 3 · · Simply Wall St.

14 Aug

Impact 3 · · Zacks
Impact 3 · · GlobeNewswire

31 Jul

Impact 3 · · Simply Wall St.

30 Jul

Impact 4 · · GlobeNewswire

11 Jul

Impact 4 ·

2 Jul

Impact 4 · · GlobeNewswire

11 May

Impact 4 ·

8 May

Impact 3 ·

25 Apr

Impact 4 · · GlobeNewswire

20 Mar

Impact 3 ·

7 Mar

Impact 3 ·

6 Mar

Impact 3 ·

19 Feb

Impact 4 ·

13 Feb

Impact 3 ·

6 Jan

Impact 4 ·
stockrow.com/YARW · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com